» Articles » PMID: 2594683

Quantitative Whole-body Autoradiographic Determination of Tacrine Tissue Distribution in Rats Following Intravenous or Oral Dose

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 1989 Nov 1
PMID 2594683
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Tacrine (1,2,3,4-tetrahydro-9-acridinamine) has been employed in diverse clinical situations but has recently been of considerable interest for the treatment of cognitive deficits associated with senile dementia (Alzheimer's disease). The present studies examined tissue distribution of radiolabeled tacrine by quantitative whole-body autoradiography. Tacrine radioequivalents were widely distributed to tissue following iv or peroral dose, with an apparently prolonged absorption phase following po dose. The presence of high levels of activity in kidneys and ureters indicates a major role for urinary excretion, but there is also evidence for biliary excretion and direct secretion of compound or metabolites into the intestinal lumen. Tacrine was rapidly taken up into the brain and demonstrated regional localization to cortex, hippocampus, thalamus, and striatum. Although the inhibition of acetylcholinesterase by tacrine is well documented, regional uptake in brain did not correlate consistently with distribution of the enzyme, supporting suggestions by others that the alleged action of tacrine in treatment of senile dementia may be by mechanisms other than cholinesterase inhibition.

Citing Articles

Diamine oxidase knockout mice are not hypersensitive to orally or subcutaneously administered histamine.

Karer M, Rager-Resch M, Haider T, Petroczi K, Gludovacz E, Borth N Inflamm Res. 2022; 71(4):497-511.

PMID: 35303133 PMC: 8989821. DOI: 10.1007/s00011-022-01558-2.


Molecular imaging identifies age-related attenuation of acetylcholine in retrosplenial cortex in response to acetylcholinesterase inhibition.

Vallianatou T, Shariatgorji M, Nilsson A, Fridjonsdottir E, Kallback P, Schintu N Neuropsychopharmacology. 2019; 44(12):2091-2098.

PMID: 31009936 PMC: 6887892. DOI: 10.1038/s41386-019-0397-5.


Spatial Quantitation of Drugs in tissues using Liquid Extraction Surface Analysis Mass Spectrometry Imaging.

Swales J, Strittmatter N, Tucker J, Clench M, Webborn P, Goodwin R Sci Rep. 2016; 6:37648.

PMID: 27883030 PMC: 5121636. DOI: 10.1038/srep37648.


A recursive-partitioning model for blood-brain barrier permeation.

Mente S, Lombardo F J Comput Aided Mol Des. 2005; 19(7):465-81.

PMID: 16331406 DOI: 10.1007/s10822-005-9001-7.


Acetylcholinesterase inhibitors in Alzheimer's disease.

McGleenon B, Dynan K, Passmore A Br J Clin Pharmacol. 1999; 48(4):471-80.

PMID: 10583015 PMC: 2014378. DOI: 10.1046/j.1365-2125.1999.00026.x.


References
1.
Davis K, Mohs R, Tinklenberg J . Enhancement of memory by physostigmine. N Engl J Med. 1979; 301(17):946. DOI: 10.1056/NEJM197910253011722. View

2.
Drukarch B, Leysen J, Stoof J . Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life Sci. 1988; 42(9):1011-7. DOI: 10.1016/0024-3205(88)90431-6. View

3.
Summers W, Kaufman K, Altman Jr F, Fischer J . THA--a review of the literature and its use in treatment of five overdose patients. Clin Toxicol. 1980; 16(3):269-81. DOI: 10.3109/15563658008989949. View

4.
Shaw F, Bentley G . The pharmacology of some new anti-cholinesterases. Aust J Exp Biol Med Sci. 1953; 31(6):573-6. DOI: 10.1038/icb.1953.62. View

5.
Kaul P . Estimation and urinary excretion of tetrahydroaminoacridine. J Pharm Pharmacol. 1962; 14:237-42. DOI: 10.1111/j.2042-7158.1962.tb11085.x. View